Aprogen Patents

Patent portfolio assigned to Aprogen (verified via public assignee records). Estimated patent count: 102. South Korean biosimilar/biologics developer. Competitors and partners (Nichi-Iko for GS071 infliximab biosimilar distribution in Japan; Schnell Life Sciences in Korea) per intuitionlabs profile; biosimilar peers Celltrion/Samsung Bioepis per GaBI. Patents confirmed: GreyB reports 102 patents globally, 71 granted; Justia also lists Aprogen Inc patents (anti-CD43 antibody, anthrax toxin antibodies).